Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
By Ben Glickman
Shares of Bluebird bio fell after the company's sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor's treatment.
The stock was down 41% to $2.84 on Friday. Shares are down 60% this year.
The company's Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology.
The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug.
Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.
Evercore analysts said in a research note that the announcements gave Casgevy an advantage because of its lack of black-box label and lower price.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 08, 2023 15:56 ET (20:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks